





FAX Completed Form To 1.833.404.2392 **Prescriber Help Desk**

Online covermymeds.com/main/

prior-authorization-forms/

1.833.587.2012

Request for Prior Authorization ELUXADOLINE (VIBERZI™)

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB					
Patient address							
Provider NPI	Prescriber name	Phone					
Prescriber address		Fax					
Pharmacy name	Address	Phone					
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.							
Pharmacy NPI	Pharmacy fax NDC						

Prior authorization is required for eluxadoline (Viberzi™). Only FDA approved dosing will be considered. Payment will be considered under the following conditions:

- 1) Patient meets the FDA approved age; and
- 2) Patient has a diagnosis of irritable bowel syndrome with diarrhea (IBS-D); and
- 3) Patient does not have any of the following contraindications to therapy:
 - Patient is without a gallbladder
 - Known or suspected biliary duct obstruction, or sphincter of Oddi disease/dysfunction
 - Alcoholism, alcohol abuse, alcohol addiction, or consumption of more than 3 alcoholic beverages per day
 - A history of pancreatitis or structural diseases of the pancreas (including known or suspected pancreatic duct obstruction)
 - Severe hepatic impairment (Child-Pugh Class C)
 - Severe constipation or sequelae from constipation
 - Known or suspected mechanical gastrointestinal obstruction; and
- 4) Patient has documentation of a previous trial and therapy failure at a therapeutic dose with both of the following:
 - A preferred antispasmodic agent (dicyclomine or hyoscyamine) and
 - A preferred antidiarrheal agent (loperamide).

If the criteria for coverage are met, initial authorization will be given for 3 months to assess the response to treatment. Requests for continuation therapy will require the following:

- Patient has not developed any contraindications to therapy (defined above); and
- Patient has experienced a positive clinical response to therapy as demonstrated by at least one of the following:
 - a) Improvement in abdominal cramping or pain, and/or
 - b) Improvement in steel frequency and consistency

ents would r

, .					
•	d trials may be ove y contraindicated.	rridden when documented evider	nce is provided that	the use of these age	
Non-Preferr	<u>ed</u>				
Viberzi					
	Strength	Dosage Instructions	Quantity	Days Supply	
Rev 6/21				Page	

F e 1 of 2







1.833.404.2392 **Prescriber Help Desk**

FAX Completed Form To

1.833.587.2012

Online

covermymeds.com/main/ prior-authorization-forms/

Request for Prior Authorization-Continued **ELUXADOLINE (VIBERZI™)**

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Diagnosis:				_	
Treatment failures:					
Antispasmodic Trial (dicyclomine or hyoscyamine):					
Drug name & dose: Trial o			l dates:		
Reason for failure:					
Antidiarrheal Trial (loperamide): Dose: Trial dates:					
Reason for failure:					
Indicate if patient has any of the following contraindications to there	ару:				
tient is without a gallbladder:			No	Yes	
Known or suspected biliary duct obstruction, or sphincter of Oddi disease/dysfunction		tion:	No	Yes	
Alcoholism, alcohol abuse, alcohol addiction, or consumption of more than 3 alcoholic beverages per day:				Yes	
A history of pancreatitis or structural diseases of the pancreas (including known or suspected pancreatic duct obstruction):			No	Yes	
Severe hepatic impairment (Child-Pugh Class C):			No	Yes	
Severe constipation or sequelae from constipation:			No	Yes	
Known or suspected mechanical gastrointestinal obstruction:			No	Yes	
Renewal Requests					
Has patient developed any contraindications to therapy (defined ab	ove)?				
☐ No ☐ Yes (document contraindications to therapy):					
Has patient experienced a positive clinical response to therapy as d Improvement in abdominal cramping or pain Improvement in stool frequency and consistency	lemonsti	rated by at ∣	least o	ne of the following?	
Possible drug interactions/conflicting drug therapies:					
Attach lab results and other documentation as necessary.					
Prescriber signature (Must match prescriber listed above.)	D	ate of submi	ssion		

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

Rev 6/21 Page 2 of 2